Recurrence morbidity of olfactory neuroblastoma

Katie Melder, LSU Health Sciences Center - New OrleansFollow
Jess C. Mace, Oregon Health & Science University, Portland, OR
Garret Choby, University of Pittsburgh Medical Center, Pittsburgh, PA
Joao Paulo Almeida, Mayo Clinic, Jacksonville, FL
Pierre-Olivier Champagne, Université Laval, Quebec, Quebec, Canada
Erik Chan, Stanford University, Palo Alto, CA
Jeremy Ciporen, Oregon Health & Science University, Portland, OR
Mark B. Chaskes, Hofstra University, New Hyde Park, NY
Juan Fernandez-Miranda, Stanford University, Palo Alto, CA
Nicholas K. Fung, University of Pittsburgh Medical Center, Pittsburgh, PA
Paul Gardner, University of Pittsburgh Medical Center, Pittsburgh, PA
Peter Hwang, Stanford University, Palo Alto, CA
Keven Seung Ji, Oregon Health & Science University, Portland, OR
Aristotelis Kalyvas, University of Toronto, Toronto, Ontario, Canada
Keonho A. Kong, University of Mississippi Medical Center, Jackson, MI
Chirag Patel, Loyola University, Maywood, IL
Zara Patel, Stanford University, Palo Alto, CA
Maria Peris Celda, Mayo Clinic, Rochester, MN
Carlos D. Pinheiro-Neto, Mayo Clinic, Rochester, MN
Carl Snyderman, University of Pittsburgh Medical Center, Pittsburgh, PA
Brian D. Thorp, University of North Carolina, Chapel Hill, NC
Jamie J. Van Gompel, Mayo Clinic, Rochester, MN
Georgios Zenonos, University of Pittsburgh Medical Center, Pittsburgh, PA
Nathan T. Zwagerman, Medical College of Wisconsin, Milwaukee, WI
Olabisi Sanusi, Oregon Health & Science University, Portland, OR
Eric W. Wang, University of Pittsburgh Medical Center, Pittsburgh, PA
Mathew Geltzeiler, Oregon Health & Science University, Portland, OR

Document Type

Article

Publication Date

4-3-2024

Publication Title

International Forum of Allergy & Rhinology

Abstract

BACKGROUND: With modern treatment paradigms, olfactory neuroblastoma (ONB) has favorable overall survival (OS); however, the incidence of recurrence remains high. The primary aims of this study were to delineate the prognosis of recurrence of ONB and explore how recurrence subsites are associated with OS, disease-specific survival (DSS), and further recurrence. METHODS: A retrospective chart review of ONB cases from nine academic centers between 2005 and 2021 was completed. Tumor characteristics, recurrence subsites, timelines to recurrence, additional recurrences, and survival estimates were determined using descriptive and time-to-event analyses. RESULTS: A final cohort of 233 patients was identified, with 70 (30.0%) patients recurring within 50.4 (standard deviation ±40.9) months of diagnosis on average, consisting of local (50%), neck (36%), intracranial (9%), and distant (6%) recurrence. Compared with subjects without recurrence, patients with recurrence had significantly different primary American Joint Committee on Cancer T stage (p < 0.001), overall stage (p < 0.001), and modified Kadish scores (p < 0.001). Histopathology identified that dural involvement and positive margins were significantly greater in recurrent cases. First recurrence was significantly associated with worse 5-year DSS (hazard ratio = 5.62; p = 0.003), and subjects with neck or local recurrence had a significantly better DSS compared to intracranial or distant recurrence. CONCLUSIONS: Recurrent cases of ONB have significantly different stages and preoperative imaging factors. Patients with local or neck recurrence, however, have better DSS than those with intracranial or distant recurrence, independent of initial tumor stage or Hyams grade. Identifying specific factors that confer an increased risk of recurrence and DSS is important for patient counseling in addition to surveillance planning.

PubMed ID

38567900

Link to Full Text

Share

COinS